Cytocentric Blog

Cytocentric Visionaries: Dr. Adrien Moya, University of Miami

Part 2: Focusing on Cell Fate

In Part One of this two-part interview, we talk with Dr. Moya about his recent paper on the importance of proper glucose and oxygen levels for MSC in regenerative medicine constructs. [1] Here we talk about the implications of this work.

Cytocentric Visionaries: Dr. Adrien Moya, University of Miami

Part 1: Oxygen and Glucose for Engineering Tissues

Dr. Adrien Moya has just started a post-doc at the University of Miami in the lab of Paul Schiller. Here we discuss Dr. Moya’s previous work in the Osteoarticular Tuberculosis Bioengineering and Bioimaging (B2OA) lab at Diderot University in Paris. His recent publication in Stem Cells  reports use of the Cytocentric platform for to control conditions for MSC used in bone regenerative medicine applications. His paper is entitled, “Human Mesenchymal Stem Cell Failure to adapt to Glucose Shortage and Rapidly Use Intracellular Energy Reserves through Glycolysis Explains Poor Cell Survival after Implantation.” [1]

Death to Cleanrooms

Cleanrooms can be eliminated for biopharmaceutical manufacturing, if the goal of 100% closed processing can be achieved. This bold statement is from a Pharma’s Almanac article by Dr. Marc Pelletier, an internationally-recognized expert on biopharmaceutical manufacturing.

“Closed processing can be achieved either by designing closed equipment or placing the open process inside a closed system such as an isolator. Whether using traditional stainless-steel tanks that are functionally closed by CIP and SIP or using single-use (SU) systems that are closed by gamma irradiation or by housing a process within a properly conditioned isolator, these options all represent a more cost-effective strategy that represents much lower risk to the patient.”

Cytocentric Visionary: Budd Tucker, University of Iowa

Part 2: Modularity is Key to Cell Therapy Process Flexibility

Dr. Budd Tucker is the Stephen A. Wynn Associate Professor of Regenerative Ophthalmology at the Stephen A. Wynn Institute for Vision Research, University of Iowa, where his lab is working on developing cGMP-compliant production of patient-specific retinal cell regenerative medicine using Xvivo Systems from BioSpherix. The transcript was edited for length.

See Part 1 of Alicia Henn’s interview with Dr. Tucker “With iPSC and CRISPR, Leave Nobody Behind, Leave Nobody Blind” here

Cytocentric Visionary: Budd Tucker, University of Iowa

With iPSC and CRISPR, Leave Nobody Behind, Leave Nobody Blind

Dr. Budd Tucker is the Stephen A. Wynn Associate Professor of Regenerative Ophthalmology at the Stephen A. Wynn Institute for Vision Research, University of Iowa, where his lab is working on developing cGMP-compliant production of patient-specific retinal cell regenerative medicine using Xvivo Systems from BioSpherix. The transcript was edited for length.